A Phase 2 interventional study of Trilaciclib and Pirarubicin in Osteosarcoma, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-12-03.
Sponsored by Peking University People's Hospital · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Osteosarcoma by Peking University People's Hospital — 5 open to participants now, 7 under way, none of them phase 3. Osteosarcoma · Peking University People's Hospital.
Among the 26 studies in Osteosarcoma by Peking University People's Hospital, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 5 in phase 2, and was the 21st registered.
488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.
Browse Osteosarcoma studies →5 of the 26 studies in Osteosarcoma by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:
Peking University People's Hospital · Sites in China
Ages 12–65
Peking University People's Hospital · Sites in China
Ages 18–60
Peking University People's Hospital · Sites in China
Ages 12+
Peking University People's Hospital
Ages 8–70
By country, each count listing its studies:
Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.
This study: 14 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8
First in 2015; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 40 across 354 interventional studies indexed under Osteosarcoma.
Median enrollment 56 across the 12 interventional studies, 100 across the 14 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Peking University People's Hospital is the lead sponsor of 611 studies on the registry; 248 are open to participants now.
1 of the studies in Osteosarcoma by Peking University People's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07479732Peking University People's HospitalApatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma | 2027-03-05 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Osteosarcoma by Peking University People's Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.
Classic osteosarcoma is the most common primary bone malignancy. At present, osteosarcoma is usually treated with preoperative chemotherapy, surgical operation and postoperative chemotherapy. Treatment with preoperative chemotherapy is also known as neoadjuvant chemotherapy. Neoadjuvant chemotherapy has brought benefits to patients, but safety concerns are inevitable. Myelosuppression is a major factor affecting the compliance of patients treated by chemotherapy. Patients with chemotherapy-induced myelosuppression(CIM) have higher rates of infection, sepsis, bleeding, and fatigue, resulting in hospitalization, hematopoietic growth factor support, blood transfusions (red blood cells and/or platelets) and even death. In addition, CIM often leads to dose reduction and delayed administration, which limits the therapeutic dose intensity and therefore affects the anti-tumor efficacy of chemotherapy.
Currently, there are no approved treatments in osteosarcoma to prevent chemotherapy-induced cell damage. Although some treatments may help to address CIM when it occurs such as blood transfusions and growth factors, these treatments are pedigree specific, being used after hematopoietic stem progenitor cells damage and could bring additional toxicity.
Trilaciclib is a highly effective, selective and temporarily reversible inhibitor of CDK4/6. The proliferation of bone marrow hematopoietic stem cells depends on CDK4/6 activity. Bone marrow hematopoietic stem cells are blocked in the G1 phase of the cell cycle after exposure to Trilaciclib before chemotherapy is given.
Therefore, this study is conducted to evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant therapy of adding Trilaciclib to Pirarubicin and Lobaplatin
Drug: Trilaciclib · Drug: Pirarubicin · Drug: Lobaplatin
Neoadjuvant therapy of Pirarubicin and Lobaplatin
Drug: Pirarubicin · Drug: Lobaplatin
Trilaciclib: 240mg/m2, IV, within 4 hours before each chemotherapy agent infused.
Also known as: Cosela
Pirarubicin: 60 mg/m2,IV,d1-2
LobaplLatin: 40 mg/m2,,IV,d1
Incidence of grade 3/4 neutropenia
Incidence of grade 3/4 neutropenia up to 30 days
Time frame: up to 30 days
Duration of grade 3/4 neutropenia
Duration of grade 3/4 neutropenia up to 30 days
Time frame: up to 30 days
Incidence of grade 3/4 thrombocytopenia
Incidence of grade 3/4 thrombocytopenia up to 30 days
Time frame: up to 30 days
Incidence of grade 3 or 4 anemia
Incidence of grade 3 or 4 anemia up to 30 days
Time frame: up to 30 days
Incidence of febrile neutropenia
Incidence of febrile neutropenia up to 30 days
Time frame: up to 30 days
Usage of granulocyte colony-stimulating factor (G-CSF)
Utilization rate of granulocyte colony-stimulating factor (G-CSF) up to 30 days
Time frame: up to 30 days
Usage of Thrombopoietin (TPO)
Utilization rate of Thrombopoietin (TPO) up to 30 days
Time frame: up to 30 days
Usage of Erythropoietin (ESA)
Utilization rate of Erythropoietin (ESA) up to 30 days
Time frame: up to 30 days
Incidence of platelet transfusion
Incidence of platelet transfusion up to 30 days
Time frame: up to 30 days
Incidence of red blood cell transfusion
Incidence of red blood cell transfusion up to 30 days
Time frame: up to 30 days
Usage of ferralia
Utilization rate of ferralia up to 30 days
Time frame: up to 30 days
chemotherapy dose reduction of any cause
chemotherapy dose reduction rate of any cause up to 30 days
Time frame: up to 30 days
AE adverse event adverse event adverse event
adverse event
Time frame: up to 30 days
SAE
serious adverse event serious adverse event serious adverse event Serious Adverse Event
Time frame: up to 30 days
Termination of treatment caused by AE/SAE
Termination of treatment rate caused by AE/SAE
Time frame: up to 30 days
Started Nov 2024 (actual). Primary completion is estimated for Jul 2025, 8 months after the start.
Of 72 non-industry phase 2 interventional studies under Osteosarcoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 8 months is below that.
Counting every sponsor, half of 76 studies reached it within 65 months; a quarter within 40 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trilaciclib
Peking University People's Hospital →